ABSTRACT
Canine urothelial carcinoma (cUC) is one of the most malignant tumors affecting dogs; however, its proliferative mechanism is yet to be fully elucidated. The ubiquitin-proteasome system (UPS) is an important metabolic pathway regulating protein degradation, and its dysfunction leads to apoptosis. We investigated the antitumor effect of the proteasome inhibitor bortezomib, which blocks the UPS. Bortezomib inhibited cell growth in cUC cell lines by inducing apoptosis in vitro. These findings suggest the potential of bortezomib as a novel therapeutic drug for dogs with cUC.
ABSTRACT
Urothelial carcinoma (UC) is the most common malignancy of the urinary tract in dogs and has aggressive behaviour. Although human epidermal growth factor receptor 2 (HER2) is a known therapeutic target with evidence in canine UC, the efficacy of anti-HER2 antibody drugs remains unknown. This study aimed to investigate the effects of anti-HER2 antibody drugs including trastuzumab and trastuzumab emtansine (T-DM1) on canine UC cell lines in vitro and in vivo. Four canine UC cell lines (Nene, TCCUB, Love, and Sora) were used. In western blotting, HER2 protein expression was observed in all the cell lines. Although both trastuzumab and T-DM1 showed dose-dependent growth inhibitory activity in the cell lines, T-DM1 showed much stronger activity than that of trastuzumab. In flow cytometry analyses with the canine UC cell line (Sora), T-DM1 but not trastuzumab significantly increased the percentages of early and late apoptotic cells in annexin V apoptotic assays and the sub-G1 phase fraction in cell cycle analyses. For the in vivo experiment, the canine UC cells (Sora) were subcutaneously injected into nude mice. Four days after inoculation, trastuzumab, T-DM1, or vehicle was administered intraperitoneally once a week for three times. Tumour volumes were significantly smaller in the T-DM1 group compared to the trastuzumab and vehicle control groups. These findings indicate that T-DM1 exerts a stronger antitumour effect than that of trastuzumab on canine UC cells in vitro and in vivo, possibly by inducing apoptosis due to DM1.
Subject(s)
Ado-Trastuzumab Emtansine , Dog Diseases , Trastuzumab , Animals , Dogs , Dog Diseases/drug therapy , Trastuzumab/pharmacology , Trastuzumab/therapeutic use , Cell Line, Tumor , Ado-Trastuzumab Emtansine/pharmacology , Ado-Trastuzumab Emtansine/therapeutic use , Mice , Antineoplastic Agents, Immunological/pharmacology , Antineoplastic Agents, Immunological/therapeutic use , Maytansine/pharmacology , Maytansine/analogs & derivatives , Maytansine/therapeutic use , Receptor, ErbB-2/metabolism , Mice, Nude , Female , Apoptosis/drug effects , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic useABSTRACT
Podoplanin (PDPN) is a prognostic factor and is involved in several mechanisms of tumor progression in human squamous cell carcinoma (SCC). Canine non-tonsillar SCC (NTSCC) is a common oral tumor in dogs and has a highly invasive characteristic. In this study, we investigated the function of PDPN in canine NTSCC. In canine NTSCC clinical samples, PDPN overexpression was observed in 80% of dogs with NTSCC, and PDPN expression was related to ki67 expression. In PDPN knocked-out canine NTSCC cells, cell proliferation, cancer stemness, and migration were suppressed. As the mechanism of PDPN-mediated cell proliferation, PDPN knocked-out induced apoptosis and G2/M cell cycle arrest in canine NTSCC cells. These findings suggest that PDPN promotes tumor malignancies and may be a novel biomarker and therapeutic target for canine NTSCC.
Subject(s)
Carcinoma, Squamous Cell , Dog Diseases , Animals , Dogs , Humans , Membrane Glycoproteins/genetics , Membrane Glycoproteins/metabolism , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/veterinary , Cell Proliferation , BiomarkersABSTRACT
Mucosal melanoma metastasizes at an early stage of the disease in human and dog. We revealed that overexpression of podoplanin in tumor invasion fronts (IF) was related to poor prognosis of dogs with mucosal melanoma. Moreover, podoplanin expressed in canine mucosal melanoma cells promotes proliferation and aggressive amoeboid invasion by activating Rho-associated kinase (ROCK)-myosin light chain 2 (MLC2) signaling. PDPN-ROCK-MLC2 signaling plays a role in cell-cycle arrest and cellular senescence escape as a mechanism for regulating proliferation. Podoplanin induces amoeboid invasion in the IFs of mouse xenografted tumor tissues, similar to canine mucosal melanoma clinical samples. We further identified that podoplanin expression was related to poor prognosis of human patients with mucosal melanoma, and human mucosal melanoma with podoplanin-high expression enriched gene signatures related to amoeboid invasion, similar to canine mucosal melanoma. Overall, we propose that podoplanin promotes canine and human mucosal melanoma metastasis by inducing aggressive amoeboid invasion and naturally occurring canine mucosal melanoma can be a novel research model for podoplanin expressing human mucosal melanoma. IMPLICATIONS: Podoplanin could be a new therapeutic target to restrict the metastatic dissemination of canine and human mucosal melanoma.
Subject(s)
Amoeba , Melanoma , Humans , Dogs , Animals , Mice , Melanoma/pathology , Transcription Factors , Signal Transduction , Cell Line, TumorABSTRACT
Combretastatin A4 (CA4) inhibits microtubule polymerization, and clinical trials of the prodrug, CA4 disodium phosphate (CA4DP), as an anti-cancer agent have been conducted. However, CA4DP has not been marketed to date because the margin between the effective dose and the cardiotoxic dose is insufficient. Meanwhile, bromodomain-containing protein 4 (BRD4) has been reported to be required for recovery from mitotic arrests induced by anti-microtubule drugs. BRD4 has also been reported to be involved in the progression of heart failure. Therefore, we hypothesized that the combined use of CA4DP with BRD4 inhibitors can enhance the antitumor effect and attenuate CA4DP-induced cardiotoxicity. In this study, the antitumor effect and cardiotoxicity caused by the co-administration of CA4DP with JQ1, a BRD4 inhibitor, were evaluated. CA4 or JQ1 alone reduced the viability of cultured canine mammary tumor cells (CHMp-13a). Viability was further reduced by co-administration, through the suppression of c-Myc. BRD4 positivity in CHMp-13a cytoplasm showed a significant increase when treated with CA4 alone, while the increase was not significant following co-administration. In CHMp-13a xenograft-transplanted mice, co-administration of CA4DP and JQ1 suppressed tumor growth significantly. In CA4DP-induced cardiac injury model rats, echocardiography showed a CA4DP-induced decrease in cardiac function and histopathology showed cardiomyocyte necrosis. Meanwhile, these cardiac changes tended to be milder following the co-administration of CA4DP and JQ1. These results suggest that CA4DP-JQ1 co-administration enhances the antitumor effect of CA4DP while attenuating its cardiotoxicity and therefore potentially open the doors to the development of a novel cancer chemotherapy with reduced cardiotoxicity risks.
Subject(s)
Stilbenes , Transcription Factors , Animals , Humans , Dogs , Mice , Rats , Transcription Factors/metabolism , Nuclear Proteins/metabolism , Cardiotoxicity/drug therapy , Stilbenes/pharmacology , Stilbenes/therapeutic use , Cell Cycle Proteins , Tubulin Modulators/pharmacology , Azepines/pharmacology , Xenograft Model Antitumor Assays , Cell Line, Tumor , Cell ProliferationABSTRACT
Bolometers are rectification devices that convert electromagnetic waves into direct current voltage through a temperature change. A superconducting bolometer has a responsivity of approximately 106-107 V/W under cryogenic temperatures at infrared wavelengths; however, no devices have realized such a high responsivity in the sub-GHz frequency region. We describe a spin bolometer with a responsivity of (4.40 ± 0.04) × 106 V/W in the sub-GHz region at room temperature using heat generated in magnetic tunnel junctions through auto-oscillation. We attribute the unexpectedly high responsivity to a heat-induced spin-torque. This spin-torque modulates and synchronizes the magnetization precession due to the spin-torque auto-oscillation and produces a large voltage output. In our device, heat-induced spin-torque was obtained because of a large heat-controlled magnetic anisotropy change: -2.7 µJ/Wm, which is significant for enhancing dynamic range and responsivity. This study can potentially lead to the development of highly sensitive microwave detectors in the sub-GHz region.
ABSTRACT
We studied nonlinear magnetic anisotropy changes to the DC bias voltage of magnetic tunnel junctions (MTJs) with capping layers of different thermal resistances. We found that increasing the thickness of MgO capping layers (in the range 0.3-0.5 nm) in MTJs enhances the Joule heating-induced magnetic anisotropy change, which indicates an enhancement of the interfacial thermal resistance at the FeB|MgO capping layer interface. This enhanced interfacial thermal resistance may be attributed to roughness at the FeB|MgO interface. Moreover, we observed a larger power-driven magnetic anisotropy change of 3.21 µJ W-1m-1 in the MTJ with a composite MgO (0.3 nm)|W (2 nm)|MgO (0.4 nm) capping layer. This research supports methods of efficient spin manipulation of spintronic devices such as microwave devices and magnetic memories.
ABSTRACT
BACKGROUND: The natural history of allergic rhinitis has been examined in a few longitudinal studies. The purpose of the study was to investigate the course, development and remission of seasonal allergic rhinitis (SAR) over 10 successive years in middle-aged subjects. METHODS: An annual questionnaire survey on allergic rhinitis symptoms combined with an examination of specific IgE has been undertaken in a rural town in south Chiba since 1995. The analyzed subjects were 703 residents who underwent every examination in 1995, 2004 and 2005. In the last 15 years, the annual pollen count in Chiba was highest in 2005. RESULTS: The sensitization rates to cedar pollen decreased with age in the same subject groups over 10 years, but the prevalence of SAR was higher in 2005 compared with 1995. Of the 52 subjects with SAR in 1995, the symptoms had disappeared in 10 subjects in 2005. Specific IgE had converted to negative or borderline in 4 of these patients, had decreased but was still positive in 4 and was increased or unchanged in 2. During the 10-year period, 22 subjects developed SAR, of whom 12 had increased specific IgE and 10 had similar or decreased specific IgE in 2005. CONCLUSION: SAR induced by cedar pollen takes a chronic course in the majority of middle-aged patients in south Chiba, Japan. The prevalence of SAR increased over 10 years due to a high level of pollen exposure. Changes in specific IgE were not directly associated with the development or remission of SAR.